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Abstract 
 
Background: The relationship between different patterns of atrial fibrillation (AF) and early 
recurrence after an acute ischemic stroke is unclear.  
Purpose: In a prospective cohort study, we evaluated the rates of early ischemic recurrence 
after an acute ischemic stroke in patients with paroxysmal AF (PAF) or sustained AF (SAF) 
which included persistent and permanent AF. 
Methods: In patients with acute ischemic stroke, AF was categorized as PAF or SAF. 
Ischemic recurrences were the composite of ischemic stroke, transient ischemic attack and 
symptomatic systemic embolism occurring within 90 days from acute index stroke. 
Results: A total of 2,150 patients (1,155 females, 53.7%) were enrolled: 930 (43.3%) had 
PAF and 1220 (56.7%) SAF. During the 90-day follow-up, 111 ischemic recurrences were 
observed in 107 patients: 31 in patients with PAF (3.3%) and 76 with SAF (6.2%), [Hazard 
Ratio (HR) 1.86 (95% CI 1.24-2.81)]. Patients with SAF were on average older, more likely 
to have diabetes mellitus, hypertension, history of stroke/TIA, congestive heart failure, atrial 
enlargement, high baseline NIHSS-score and implanted pacemaker. After adjustment by Cox 
proportional hazard model, SAF was not associated with early ischemic recurrences [adjusted 
HR 1.23 (95% CI 0.74-2.04)]. 
Conclusions: After acute ischemic stroke, patients with SAF had a higher rate of early 
ischemic recurrence than patients with PAF. After adjustment for relevant risk factors SAF 
was not associated with a significantly higher risk of recurrence, such suggesting that the risk 
profile associated with AF more than its pattern is determinant for recurrence. 
 
Key Words: stroke, atrial fibrillation, paroxysmal atrial fibrillation, sustained atrial 
fibrillation, stroke recurrence, anticoagulation. 
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Introduction 
 
Atrial fibrillation (AF) is the most common chronic cardiac arrhythmia and the number of 
patients with AF is predicted to rise steeply in the coming years.1,2 Despite remarkable 
progresses in the management of patients with AF, this arrhythmia remains one of the major 
causes of stroke and thromboembolic events.3 
The relationship between the different patterns of AF and the risk of stroke has been analyzed 
in several studies with conflicting results. Various studies reported similar risks of 
thromboembolism for patients with paroxysmal AF (PAF) and those with sustained AF 
(SAF).4-10 However, several other studies indicated a higher risk for ischemic events in 
patients with non-paroxysmal AF compared to those with PAF.11-21 Current guidelines on AF 
management recommend that the pattern of AF should not influence the decision on whether 
to treat patients with anticoagulants.3,22  
The association of AF pattern with the risk of early recurrence after an acute ischemic stroke 
is unclear. By using RAF (Early Recurrence and Cerebral Bleeding in Patients With Acute 
Ischemic Stroke and Atrial Fibrillation) and RAF-NOAC (Early Recurrence and Cerebral 
Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation treated with Non 
Vitamin K Oral Anticoagulants) study databases23,24 we evaluated the rates of ischemic 
recurrences in patients with PAF and those with SAF within 90 days after an acute ischemic 
stroke. The ultimate aim of the study was to consider if after an acute ischemic stroke 
different treatment approaches are needed in the presence of different patterns of AF. 
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Methods 
 
For the purpose of this analysis, we combined the databases of the RAF study and the RAF-
NOAC study. RAF and RAF-NOAC were prospective observational studies carried out 
between January 2012 and March 2014 in 29 Stroke Units and between April 2014 and June 
2016 in 35 Stroke Units respectively, across Europe, United States and Asia. Both studies 
enrolled consecutive patients with acute ischemic stroke and known or newly diagnosed AF 
without contraindications to anticoagulation. The studies were approved by the local 
Institutional Review Boards, if required. 
On admission, stroke severity was assessed using the National Institutes of Health Stroke 
Scale (NIHSS). A non-contrast cerebral computed tomography (CT) or cerebral magnetic 
resonance (MR) scan was performed on admission for all patients to exclude intracranial 
hemorrhage. Revascularization treatments were given as per standard local protocol, when 
appropriate. Standard Stroke Unit care, monitoring and treatment were provided according to 
current international recommendations for acute ischemic stroke. Attending physicians made 
decisions regarding the type of anticoagulant to be used for secondary prevention, as well as 
the day of initiation of anticoagulant treatment. The RAF study included patients treated with 
either vitamin K antagonists or NOACs while the RAF-NOAC study included only patients 
who received NOACs.  
A full history and clinical examination, admission ECG and prolonged ECG monitoring for 
48 h after the index stroke were performed to detect non-valvular atrial fibrillation. AF was 
categorized as: 
(1) paroxysmal: associated with episodes terminating spontaneously within 7 days; 
(2) persistent: associated with episodes lasting more than 7 days or requiring 
pharmacological and/or electrical cardioversion; 
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(3) permanent: persisting for more than 1 year, either because cardioversion failed or was 
not pursued.25 
For the purpose of the present study, AF was categorized into two types: paroxysmal AF or 
sustained (persistent or permanent) AF. 
A second brain CT scan or MR was scheduled to be performed 24-72 h from stroke onset in 
all patients. The sites and sizes of the qualifying infarcts were determined based on standard 
templates as: 
(1) small: when a lesion was ≤ 1.5 cm in the anterior or posterior circulation;  
(2) medium: when a lesion was in a cortical superficial branch of middle cerebral artery, 
in the middle cerebral artery deep branch, in the internal border zone territories, in a 
cortical superficial branch of posterior cerebral artery, in a cortical superficial branch of 
the anterior cerebral artery; 
(3) large anterior: when a lesion involved the complete territory of middle, posterior, or 
anterior cerebral artery; in 2 cortical superficial branches of middle cerebral artery; in a 
cortical superficial branch of middle cerebral artery associated to the middle cerebral 
artery deep branch, or in more than 1 artery territory; 
(4) large posterior: when a lesion was ≥ 1.5 cm in the brain stem or cerebellum.26 
Left atrial enlargement and its severity was defined following the American Society of 
Echocardiography guidelines measuring the left atrial diameter or volume taking into account 
the difference between sexes.27 
 
Risk factors. Data on known stroke risk factors were collected as follows: age, gender, 
history of hypertension (blood pressure of ≥ 140/90 mmHg at least twice before stroke or 
already under treatment with antihypertensive drugs), history of diabetes mellitus (fasting 
glucose level ≥ 126 mg/dL pre-prandial on 2 examinations, glucose level ≥ 200 mg/dL 
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postprandial, or HbA1c ≥ 6.5%, or under antidiabetic treatment), current cigarette smoking, 
past smoking (cessation less than 5 years ago), hyperlipidemia (total cholesterol ≥ 200 mg/dL 
or triglyceride ≥ 140 mg/dL or already under lipid lowering therapy), history of symptomatic 
ischemic heart disease (myocardial infarction, history of angina or existence of multiple 
lesions on thallium heart isotope scan or evidence of coronary disease on coronary 
angiography), history of symptomatic peripheral arterial disease (intermittent claudication of 
presumed atherosclerotic origin; or ankle/arm systolic blood pressure ratio < 0.85 in either 
leg at rest; or history of intermittent claudication with previous leg amputation, reconstructive 
surgery, or angioplasty), alcohol abuse (≥ 300 g per week), obesity (body mass index ≥ 30 
kg/m2), or previous stroke/TIA. White matter changes [leukoaraiosis defined on the first CT 
(or MR) examination as ill-defined and moderately hypodense (or hyperintensity on T2-
weighted on MR) areas of ≥ 5 mm according to published criteria] were investigated. 
Leukoaraiosis in the deep white matter was dichotomized into absent versus present 
(independently if mild, moderate, or severe).28 Other baseline variables obtained at admission 
for all patients included: fasting serum glucose, fasting serum cholesterol (total, HDL, and 
LDL), platelet count, international normalized ratios (INR), activated partial thromboplastin 
time (aPTT), systolic blood pressure, and diastolic blood pressure. 
Data on the use of any antiplatelet, anticoagulants or thrombolytic agent, prior to admission, 
at baseline and during the follow-up period, were recorded. 
The CHA2DS2-VASc score (2 points for history of stroke or age ≥ 75 years and 1 point each 
for congestive heart failure, hypertension, diabetes, vascular disease, age 65 to 74 years and 
female sex) was calculated before and after the index event. 
 
Evaluation of outcome. Patients were followed-up prospectively by face-to-face or 
telephone interviews. Whether an outcome event occurred, patients were requested to bring 
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full documentation of it to a face-to-face appointment. Study outcome at 90 days was the 
composite of: recurrent ischemic cerebrovascular events (stroke or TIA) and symptomatic 
systemic embolism. 
Stroke was defined as the sudden onset of a new focal neurological deficit of vascular origin 
in a site consistent with the territory of a major cerebral artery and categorized as ischemic or 
hemorrhagic. TIA was defined as a transient episode of neurological dysfunction caused by 
focal brain ischemia without acute infarction. Systemic embolism was defined as an acute 
vascular occlusion of an extremity or organ confirmed by imaging, surgery, or autopsy.  
 
Statistical analyses. Population characteristics were summarized as mean and SD for 
continuous variables and as absolute numbers and percentages for categorical variables.  
Differences in the baseline characteristics of patients with PAF or SAF were tested using 2 
test for nominal variables, or ANOVA for continuous variables. Specifically, univariate tests 
were utilized to compare both clinical characteristics on admission and pre-existing risk 
factors for PAF.  
A multivariate analysis was performed using logistic regression to determine independent 
predictors of PAF. 
Differences in the characteristics of patients with or without ischemic recurrence at 90 days 
were tested using 2 test for nominal variables or ANOVA for continuous variables. 
Specifically, univariate tests were used to compare both clinical characteristics on admission 
and pre-existing risk factors for ischemic events. 
The relationship between the survival function and the set of explanatory variables were 
explored with Cox proportional hazard model. Cox model provided estimates of AF pattern 
influence on survival after adjusting for other explanatory variables.  
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In order to measure associations, we used odds ratios (OR) for multivariate logistic models 
and hazard ratios (HR) for survival curve analyses with a 95% confidence interval; a two-
sided P value < 0.05 was considered significant. 
All statistical analyses were performed using the IBM SPSS Statistics version 22.0 (IBM 
Corporation, Somers, NY). 
 
Results 
 
PAF versus SAF patients. A total of 2,150 patients (1,155 women, 53.7%) were enrolled. 
Among these, 930 (43.3%) had paroxysmal (360 in RAF, 570 in RAF-NOAC) and 1,220 
(56.7%) sustained AF (660 in RAF, 560 in RAF-NOAC).  
812 patients with PAF (87.3%) and 976 patients with SAF (80.0%) received OAC, of which 
592 and 630 were NOACs, respectively. VKAs included warfarin (518) and acenocumarol 
(49), whereas NOACs included rivaroxaban (414), dabigatran (410) and apixaban (396). 
The baseline characteristics of the patients with PAF and SAF are summarized in Table 1. 
Patients with SAF were on average older and more likely to have the following: higher 
baseline NIHSS-score, diabetes mellitus, hypertension, a history of stroke/TIA, congestive 
heart failure, pacemaker implanted, CHA2DS2-VASc > 4 and atrial enlargement (all p < 
0.05). Patients with PAF were more likely to be on OAC treatment after the index stroke. 
The results from the multivariate analysis for factors associated with SAF are listed in Table 
2. Older age, diabetes mellitus, history of stroke/TIA, alcoholism, history of congestive heart 
failure and pacemaker implant were all significant factors associated with SAF.  
 
Ischemic recurrences. Over 90 days of follow-up, 111 ischemic recurrences were recorded 
in 107 patients (82 ischemic strokes, 18 TIAs and 11 systemic embolisms). The baseline 
characteristics of patients with and without ischemic events within 90 days from acute stroke 
 11 
are listed in Table 3. Patients with ischemic recurrence were on average older and were more 
likely to have: higher baseline NIHSS-score, diabetes mellitus, hypertension, congestive heart 
failure, pacemaker implanted and CHA2DS2-VASc score > 4. Patients without ischemic 
recurrence were more likely to have small size lesions, to be on OAC treatment after the 
index stroke and to have PAF. 
Among patients who suffered an ischemic recurrence, 9.1% (34/372) had not started 
anticoagulation therapy, 6.7% (38/563) were treated with a VKA and 2.9% (35/1220) with a 
NOAC. The median time for starting OAC was 8 days in patients with PAF and 6 days in 
patients with SAF. 
Cox proportional hazard model was adjusted for age, sex, diabetes, hypertension, 
hyperlipidemia, history of stroke, current smoking, alcoholism, history of congestive heart 
failure, myocardial infarction, pacemaker implant, small lesion size and type of 
anticoagulant. SAF did not result as a risk for ischemic recurrence when compared with PAF 
(HR 1.23; 95% CI 0.74-2.04; p = 0.418) (Figure 1). The same result was obtained excluding 
TIAs from outcomes (HR 1.11; CI 0.60-2.12; p = 0.7). A sensitivity analysis performed to 
evaluate if our results were consistent when SAF was categorized as either persistent (HR 
1.33; 95% CI 0.70-2.51; p = 0.387) or permanent AF (HR 1.12; 95% CI 0.61-2.04; p = 0.715) 
confirmed that AF pattern is not associated with ischemic recurrence (Figure 2).  
 
Discussion 
 
Among patients with acute ischemic stroke, those with SAF had a higher rate of early 
ischemic recurrence than patients with PAF. After adjustment for risk factors for early 
ischemic recurrence, SAF was not associated with a significantly higher risk of recurrence.  
Recent studies have reported a higher risk for ischemic events in patients with non-
paroxysmal AF compared to those with PAF.11-14,17,19-21 The large majority of the patients 
 12 
included in these studies did not have a previous stroke and were evaluated for a long-term 
follow-up. In contrast, our study was focused on early recurrence in patients with recent 
ischemic stroke followed-up for 90 days. 
The vast majority of patients enrolled in the RAF and RAF-NOAC studies were prescribed 
with anticoagulation therapy (81.6%) after the index stroke. Anticoagulation reduces the rates 
of ischemic outcome and therefore, although our study mirrors clinical practice, it might not 
reflect the natural history of the disease. Evaluating a group of AF patients in absence of 
anticoagulation might better reflect the recurrence risk in different types of AF,21 but such a 
study design would not be feasible in populations at high risk of ischemic events, like cohorts 
on secondary prevention. 
On average, in this cohort patients with SAF started OAC therapy 2 days before those with 
PAF; this could have influenced the event rate. However, this effect was, in our opinion, 
marginal. 
The EORP-AF General Pilot Registry reported a worse outcome in patients with SAF in 
comparison to patients with PAF. However, this difference did not seem to be associated to 
the pattern of the arrhythmia, but to the worse clinical risk profile in terms of age, underlying 
cardiac disease, and other clinical risk factors.29 Likewise, a sub-analysis of the J-RHYTHM 
Registry reported that thromboembolic events occurred more frequently in the permanent AF 
group, particularly in patients with higher CHA2DS2-VASc score. In that study, after 
adjusting for CHA2DS2-VASc score components and anticoagulation treatment, the risk of 
ischemic events did not differ between PAF and permanent AF.9 Our present findings in 
patients on secondary prevention are in line with the results of these two primary prevention 
studies: in particular, patients with SAF were on average older and were more likely to have 
diabetes mellitus, hypertension, history of stroke/TIA, and congestive heart failure. After 
adjusting for established risk factors, the early thromboembolic risk in patients with acute 
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ischemic stroke was not associated with a particular AF pattern. These findings suggest that 
AF pattern should not influence the decision regarding the timing of initiating anticoagulation 
treatment after an acute ischemic stroke.  
Study limitations. Our study had several limitations. First, the associations shown in this 
non-randomized study were most likely influenced by several confounders, although adjusted 
statistical models were used to partially control them. Second, a central adjudication of the 
outcome events was not performed but rather these events were assessed by the local 
investigators. This approach is quite common in investigator-initiated cohort prospective 
studies and may be justified provided that validated and internationally recognized definitions 
of events are actually used. This was the case of our study. Third, the inclusion of TIA as 
ischemic recurrence, which is considered as a soft endpoint, may have also influenced the 
reported associations, but sensitivity analysis performed excluding TIAs as outcome gave 
similar results. 
Strengths of our study included the prospective design, the multicenter nature and its 
relatively large sample size. 
 
Conclusions 
 
Among patients with acute ischemic stroke, patients with PAF had a lower rate of early 
ischemic recurrence than patients with SAF. After adjustment for risk factors for early 
ischemic recurrence, SAF was not associated with a significantly higher risk of recurrence. 
Our results suggest that, when making decision about the timing to initiate anticoagulation 
treatment after an acute ischemic stroke, the patient’s risk profile should be given greater 
relevance than the pattern of AF. These results support the need for additional comparative 
studies, including randomized trials. 
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Figures  
 
 
Figure 1: Adjusted cumulative risk for ischemic recurrence (stroke, transient ischemic attack, 
systemic embolism) in patients with SAF compared with patients with PAF (HR 1.23; 95% 
CI 0.74-2.04; p = 0.418). AF = atrial fibrillation; HR = hazard ratio; PAF = paroxysmal atrial 
fibrillation; SAF = sustained atrial fibrillation. 
  
 2 
 
 
Figure 2: Adjusted cumulative risk for ischemic recurrence in patients with paroxysmal, 
permanent and persistent AF; AF = atrial fibrillation. 
 
Table 1. Baseline characteristics of patients with PAF and SAF 
 PAF 
(n = 930) 
SAF 
(n = 1220) 
p* 
Age (mean, years) 74.5 ± 9.8 77.7 ± 9.5 < 0.0001 
Sex M 422 (45.4%) 573 (47.0%)  
NIHSS (mean) 8.0 ± 6.7 8.7 ± 6.8 0.026 
Diabetes mellitus 181 (19.5%) 301 (24.7%) 0.004 
Hypertension 709 (76.2%) 978 (80.2%) 0.026 
Hyperlipidemia 318 (34.2%) 405 (33.2%)  
History stroke/TIA 211 (22.7%) 357 (29.3%) 0.001 
Current smoker 110 (11.8%) 95 (7.8%)  
Alcoholism 50 (5.4%) 92 (7.5%)  
History congestive heart failure 89 (9.6%) 281 (23.0%) < 0.0001 
History myocardial infarction 116 (12.5%) 180 (14.8%)  
History peripheral artery disease 71 (7.6%) 111 (9.1%)  
Pacemaker 39 (4.2%) 111 (9.1%) < 0.0001 
Lesion size    
      Small 350 (37.6%) 471 (38.6%)  
      Medium 310 (33.3%) 428 (35.1%)  
      Large Anterior 173 (18.6%) 225 (18.4%)  
      Large Posterior 62 (6.7%) 74 (6.1%)  
Leukoaraiosis 465 (50.0%) 632 (51.8%)  
OAC 812 (87.3%) 976 (80.0%) < 0.0001 
      VKA 220 (23.7%) 346 (28.4%)  
      NOAC 592 (63.7%) 630 (51.6%) < 0.0001 
CHA2DS2-VASc > 4 682 (73.3%) 988 (81.0%) < 0.0001 
Atrial enlargement †  
 
510 (62.5%) 739 (74.6%) < 0.0001 
 
* p-values are given only if < 0.05; † 1806 patients with trans-thoracic echocardiogram performed. 
NIHSS = National Institutes of Health Stroke Scale; PAF = paroxysmal atrial fibrillation; SAF = 
sustained atrial fibrillation; TIA = transient ischemic attack. 
Table 2. Multivariate logistic regression analysis of factors potentially associated with SAF 
 
 OR 95% CI p* 
Age (for each year increase) 1.03 1.02-1.04 < 0.0001 
Sex 1.15 0.94-1.39  
NIHSS 1.01 1.00-1.03  
Diabetes mellitus 1.28 1.03-1.61 0.026 
Hypertension 1.05 0.79-1.25  
Hyperlipidemia 3.85 0.73-1.09  
History stroke/TIA 1.25 1.01-1.54 0.042 
Smoking 3.85 0.79-1.06  
Alcoholism 1.69 1.14-2.50 0.009 
History congestive heart failure 2.70 2.04-3.57 < 0.0001 
History myocardial infarction 3.85 0.64-1.12  
Pacemaker 1.85 1.23-2.78 0.003 
 
* p-values are given only if < 0.05. CI = confidence interval; OR = odds ratios; other abbreviations 
as in Table 1. 
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Table 3. Baseline characteristics of patients with and without ischemic recurrences 
 
 With event 
(n = 107) 
Without event 
(n = 2040) 
p* 
Age (mean, years) 78.3 ± 9.4 76.2 ± 9.8 0.034 
Sex M 47 (43.9%) 945 (46.3%)  
NIHSS (mean) 10.4 ± 8.0 8.3 ± 6.7 0.001 
Diabetes mellitus 38 (35.5%) 443 (21.7%) 0.020 
Hypertension 93 (86.0%) 1597 (78.3%) 0.026 
Hyperlipidemia 37 (34.6%) 697 (34.2%)  
History stroke/TIA 35 (32.7%) 528 (25.9%)  
Current smoker 8 (7.5%) 196 (9.6%)  
Alcoholism 9 (8.4%) 131 (6.4%)  
History congestive heart failure 29 (27.1%) 340 (16.7%) 0.008 
History myocardial infarction 17 (15.9%) 275 (13.5%)  
History peripheral artery disease 14 (13.1%) 163 (8.0%)  
Pacemaker 13 (12.1%) 133 (6.5%) 0.029 
Lesion size    
      Small 31 (29.0%) 796 (39.0%) 0.050 
      Medium 
      Large Anterior 
      Large Posterior  
Leukoaraiosis 
PAF 
OAC 
42 (39.3%) 
27 (25.2%) 
3 (2.8%) 
61 (57.0%) 
31 (29.0%) 
73 (68.2%) 
705 (34.6%) 
368 (18.0%) 
132 (6.5%) 
1013 (49.7%) 
886 (43.4%) 
1710 (83.9%) 
 
 
 
 
0.003 
0.001 
      VKA 38 (35.5%) 525 (25.7%) 0.041 
      NOAC 35 (32.7%) 1185 (58.1%) 0.001 
CHA2DS2-VASc > 4 94 (87.9%) 1573 (77.0%) 0.008 
 
* p-values are given only if < 0.05. CHA2DS2-VASc = congestive heart failure, hypertension, 
75 years of age and older, diabetes mellitus, previous stroke or transient ischemic attack, 
 2 
vascular disease, 65 to 74 years of age, female; OAC = oral anticoagulation; other 
abbreviations as in Table 1. 
